Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832

OPC-167832, an inhibitor of decaprenylphosphoryl-β-d-ribose 2’-oxidase, demonstrated potent antituberculosis activity and a favorable safety profile in preclinical studies. This report describes the first two clinical studies of OPC-167832: (i) a phase I single ascending dose (SAD) and food effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawson, Rodney, Diacon, Andreas H., Narunsky, Kim, De Jager, Veronique R., Stinson, Kelly W., Zhang, Xiaoyan, Liu, Yongge, Hafkin, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269160/
https://www.ncbi.nlm.nih.gov/pubmed/37219453
http://dx.doi.org/10.1128/aac.01477-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269160/
https://www.ncbi.nlm.nih.gov/pubmed/37219453
http://dx.doi.org/10.1128/aac.01477-22

Ejemplares similares